MYL News and Press, Mylan N.V. From 01/19/20

On some levels, Rigel Pharmaceuticals (NASDAQ: RIGL) and Momenta Pharmaceuticals (NASDAQ: MNTA) are complete opposites. Rigel, based in South San Francisco, focuses on small molecule drugs while Momenta, headquartered in Cambridge, Massachusetts, tackles disease using large molecules cal...

Quick Take Aditx Therapeutics ( ADTX ) has filed to raise $10.5 million in an IPO of its common stock and warrants, according to an S-1 registration statement . The company is a pre-clinical developer of immune suppression drugs to assist in organ transplantation procedures. ADTX is sti...

Image Source: Pfizer Inc – March 2019 IR Presentation By Callum Turcan Pfizer Inc ( PFE ) yields ~3.9% as of this writing and due to the strength of its free cash flow profile, we view the big pharmaceutical company’s dividend as well-protected. Our fair value estimate si...

Mylan N.V. (MYL) 38th Annual J.P. Morgan Healthcare Conference January 15, 2020, 11:30 AM ET Company Participants Robert Coury - Executive Chairman Michael Goettler - Chief Executive Officer Rajiv Malik - President Conference Call Participants Chris Schott - J.P. Morgan ...

Mylan N.V. ( MYL +3.3% ) perks up on below-average volume on the heels of a presentation this morning at JPM20 by Executive Chairman Robert Coury that focused Viatris, its planned combination with Pfizer's ( PFE +1.3% ) Upjohn unit that is expected to close mid-year. Key points: Mo...

Drug developer Theravance Biopharma (NASDAQ: TBPH) is not your typical biotech company. It emerged in 2014 from a spinoff of the R&D branch of its parent company, now called Innoviva (NASDAQ: INVA) . Shareholders in Innoviva received a dividend of Theravance Biopharma stock. The R&am...

ETF Overview iShares U.S. Pharmaceuticals ETF ( IHE ) owns a portfolio of large-cap pharmaceutical stocks. The ETF tracks the investment results of the Dow Jones U.S. Select Pharmaceuticals Index. Stocks in IHE's portfolio are stocks with competitive advantages over their smaller peers. In a...

Shares of Mylan (NASDAQ: MYL) fell over 26% last year, according to data provided by S&P Global Market Intelligence . The generic drug manufacturer struggled to overcome its negative association in the national discussion related to drug pricing practices and became embroiled in an indu...

Apellis Pharmaceuticals ( APLS ) reported positive results from a Phase 3 clinical trial, PEGASUS , evaluating pegcetacoplan (APL-2) in adults with paroxysmal nocturnal hemoglobinuria. The trial pitted the drug directly against Alexion's Soliris and offered positive results. As per the resu...

In a move that could rock the pharmaceutical industry, California Governor Gavin Newsom announced his intent to create the first state-run prescription drug label in the U.S. This entity would theoretically leverage the size and power of the California population to negotiate advantageous prices...